CN Patent

CN119317641A — 针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药

Assigned to Genentech Inc · Expires 2025-01-14 · 1y expired

What this patent protects

本发明提供了针对用抗可结晶片段受体样5(FcRH5)/抗分化簇3(CD3)双特异性抗体治疗癌症诸如多发性骨髓瘤的给药方法。

USPTO Abstract

本发明提供了针对用抗可结晶片段受体样5(FcRH5)/抗分化簇3(CD3)双特异性抗体治疗癌症诸如多发性骨髓瘤的给药方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN119317641A
Jurisdiction
CN
Classification
—
Expires
2025-01-14
Drug substance claim
No
Drug product claim
No
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.